COMMUNIQUÉS West-GlobeNewswire

Medicana Health Group Introduces Digital Twin-Based Dental Treatment Planning
28/10/2026
Medicana Health Group ’s Associate Professor İlhan Metin Dağsuyu explains how virtual models can help patients understand proposed dental treatment while keeping natural teeth and function at the centre of decisions. [...]
Flexi Yoga App Launches Personalized Flexibility and Mobility App
28/10/2026
New Flexi Yoga App Turns a Short Quiz Into a Daily Stretching and Mobility Routine NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Flexi Yoga has launched a personalized wellness app designed to improve flexibility, [...]
Novato-based Live Oaks Wellness encourages year-round prevention with family engagement and community-based prevention efforts for substance abuse
28/10/2026
National Substance Abuse Prevention Month Goes Beyond Addiction Awareness NOVATO, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- The month of October celebrates an important national recognition that goes beyond just [...]
$20,000 donated by Saskatchewan Blue Cross to six local organizations
28/10/2026
SASKATOON, Saskatchewan, Oct. 28, 2026 (GLOBE NEWSWIRE) -- A simple click can make a big impact. This year, those clicks translated into $20,000 in funding for six Saskatchewan organizations. Through Saskatchewan Blue [...]
AdipoPharma lance la phase 1b des essais cliniques du peptide PATAS chez des patients atteints de diabète de type 2
28/10/2026
Les premiers participants atteints de diabète de type 2 ont reçu leur première dose dans le cadre d’une étude à doses multiples croissantes (MAD) évaluant le premier sensibilisateur à l’insuline de sa catégorie [...]
Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program
28/10/2026
EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research VANCOUVER, British Columbia, Oct. 28, 2026 (GLOBE [...]
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
28/10/2026
BOSTON and SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline
28/10/2026
ORION CORPORATION INTERIM REPORT 1–9/2026 28 OCTOBER 2026 at 12:00 EET Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline July–September [...]
Digbi Health Announces ASRA, a Precision Biology-Powered Agentic Care Operating System Unifying Metabolic, Inflammatory, and Hormonal Health
28/10/2026
Built on three years of development and testing and billions of linked biological, clinical, lifestyle, and behavioral data points, ASRA brings together Precision Biology, AI-driven operations, and clinician-supervised [...]
Beyond the Ballot: More Than 3,500 Back OHIP Petition as Psychotherapy Gaps Come Into Focus
28/10/2026
Following the province’s response to CBC, a Guelph-led campaign asks what happens to people who need treatment outside existing programs. GUELPH, Ontario, Oct. 28, 2026 (GLOBE NEWSWIRE) -- More than 3,500 people have [...]
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
28/10/2026
Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases SAN DIEGO and [...]
Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
28/10/2026
BURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
28/10/2026
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results [...]
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
28/10/2026
TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass., Oct. 28, 2026 (GLOBE [...]
Remix Therapeutics Selected for Late-Breaking Oral Presentation at the 38th EORTC-NCI-AACR Symposium
28/10/2026
Presentation to Include Updated Interim Data from Ongoing Phase 1/2 ARIA Study of REM-422 in Adenoid Cystic Carcinoma WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical- [...]
BPGbio Publishes Pioneering Research on Novel Brain-Penetrant Therapeutic Candidate for Glioma
28/10/2026
Preclinical study demonstrates potent anticancer activity, blood-brain barrier penetration, and improved survival in glioma models Findings highlight a novel therapeutic approach targeting microtubule dynamics, with [...]
Lumexa Imaging Announces Third Quarter 2026 Earnings Conference Call Date
28/10/2026
RALEIGH, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced it will release its third quarter 2026 financial and [...]
NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer
28/10/2026
Biotechnology Executive Brings Extensive Capital Markets, Financing, Corporate Strategy and Investor Relations Experience ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences, Inc. (“NovaBridge” or [...]
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
28/10/2026
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum